A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso) in Subjects With Pulmonary Arterial Hypertension

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso) in Subjects With Pulmonary Arterial Hypertension

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Beraprost (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms BEAT
  • Sponsors Lung Biotechnology
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Feb 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top